Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VU Q PHAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1831247667
CMS profile
37451
Location
LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$8,596.02

277 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $6,555.18 272
Consulting Fee $1,650.00 1
Education $390.84 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Cardinal Health 110 LLC $2,015.24 4
AstraZeneca Pharmaceuticals LP $541.36 22
PFIZER INC. $417.36 24
Merck Sharp & Dohme LLC $404.39 17
Janssen Biotech, Inc. $361.46 14
ABBVIE INC. $317.36 12
Dendreon Pharmaceuticals LLC $297.42 8
Celgene Corporation $276.04 27
Incyte Corporation $245.36 8
BeiGene USA, Inc. $215.42 5
Daiichi Sankyo Inc. $213.39 7
Genentech USA, Inc. $150.47 7
Gilead Sciences, Inc. $147.83 9
Regeneron Healthcare Solutions, Inc. $142.53 4
Bayer Healthcare Pharmaceuticals Inc. $134.30 6
Adaptive Biotechnologies Corporation $120.63 2
Aveo Pharmaceuticals, Inc. $118.64 2
Exelixis Inc. $117.65 5
ARRAY BIOPHARMA INC $116.47 7
Eisai Inc. $113.84 4
Lilly USA, LLC $112.35 4
Tempus AI, Inc $109.71 4
Boston Scientific Corporation $106.62 3
Cardinal Health 108 LLC $95.60 1
PharmaEssentia USA Corporation $90.17 3
Organon Llc $89.39 6
Genmab U.S., Inc. $89.00 3
PUMA BIOTECHNOLOGY, INC. $87.14 4
Takeda Pharmaceuticals U.S.A., Inc. $83.93 3
Boehringer Ingelheim Pharmaceuticals, Inc. $81.85 3
Spectrum Pharmaceuticals Inc. $80.06 3
SpringWorks Therapeutics, Inc. $74.19 3
Stemline Therapeutics Inc. $70.22 2
Alexion Pharmaceuticals, Inc. $69.89 3
Ipsen Biopharmaceuticals, Inc $66.93 3
Immunocore Limited $66.32 2
Rigel Pharmaceuticals, Inc. $65.85 3
JAZZ PHARMACEUTICALS INC. $59.66 2
GENZYME CORPORATION $59.05 2
GlaxoSmithKline, LLC. $56.57 3
Karyopharm Therapeutics Inc. $54.65 3
SOBI, INC $50.85 2
Blueprint Medicines Corporation $50.56 2
EMD Serono, Inc. $46.46 1
Astellas Pharma US Inc $45.56 2
Pharmacosmos Therapeutics Inc. $44.40 2
Coherus Biosciences Inc. $40.41 2
TAIHO ONCOLOGY, INC. $34.65 2
ADC Therapeutics America, Inc. $29.60 2
Amneal Pharmaceuticals LLC $28.71 1
Sirtex Medical Inc $28.68 1
Sumitomo Pharma America, Inc. $23.20 1
E.R. Squibb & Sons, L.L.C. $21.79 1
ImmunoGen, Inc. $14.84 1

Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VU Q PHAN

NPI 1831247667 · CMS profile ID 37451

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VU Q PHAN, NPI 1831247667, CMS profile ID 37451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). VU Q PHAN, NPI 1831247667, CMS profile ID 37451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
VU Q PHAN, NPI 1831247667, CMS profile ID 37451, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

277 matching records · $8,596.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 277 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–277 of 277.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $32.6801/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141761113 CMS
PFIZER INC. $29.6701/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294854 CMS
Celgene Corporation $11.4101/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101122192 CMS
ImmunoGen, Inc. $14.8401/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1099941755 CMS
Merck Sharp & Dohme LLC $26.3901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141760931 CMS
PharmaEssentia USA Corporation $29.2001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137310776 CMS
Incyte Corporation $15.0001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141299025 CMS
Janssen Biotech, Inc. $12.5101/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078305650 CMS
GlaxoSmithKline, LLC. $17.9901/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116311469 CMS
PUMA BIOTECHNOLOGY, INC. $20.6501/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113856383 CMS
PFIZER INC. $17.9401/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130894103 CMS
Astellas Pharma US Inc $17.8501/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139289340 CMS
Organon Llc $14.2901/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136239004 CMS
Lilly USA, LLC $34.7101/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135440979 CMS
Tempus AI, Inc $29.5001/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150171969 CMS
Merck Sharp & Dohme LLC $18.2201/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141761101 CMS
Celgene Corporation $23.4401/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101122186 CMS
Spectrum Pharmaceuticals Inc. $28.5201/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150656213 CMS
AstraZeneca Pharmaceuticals LP $23.4701/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104230479 CMS
AstraZeneca Pharmaceuticals LP $20.5001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104618524 CMS
Merck Sharp & Dohme LLC $32.1101/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141761117 CMS
Genmab U.S., Inc. $30.9401/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833303 CMS
Regeneron Healthcare Solutions, Inc. $33.7601/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114137090 CMS
Cardinal Health 110 LLC $1,650.0001/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100223261 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.1501/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144965141 CMS
Dendreon Pharmaceuticals LLC $29.8401/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322157 CMS
Dendreon Pharmaceuticals LLC $28.6601/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322159 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,470.43 138
PY2020 $1,911.15 98
PY2021 $5,528.91 144
PY2022 $4,601.74 209
PY2023 $5,904.49 247
PY2024 $8,596.02 277
PY2025 $12,548.18 297

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,939,793.98 75
PY2024 Principal investigator $531,983.19 16
PY2023 Recipient $291.47 2
PY2023 Principal investigator $145,754.35 29
PY2022 Recipient $2,011.00 2
PY2022 Principal investigator $100,356.80 9
PY2021 Principal investigator $79,408.52 2
PY2020 Principal investigator $33,128.52 2
PY2019 Principal investigator $41.72 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $124,764.90 12/26/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175436392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,689.78 12/11/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274574
Principal investigator 1 Janssen Research & Development, LLC $8,057.00 12/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436398
Principal investigator 1 Janssen Research & Development, LLC $6,800.00 12/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436809
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,894.00 12/03/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1235998450
Principal investigator 1 Janssen Research & Development, LLC $86,087.00 12/01/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,489.98 11/25/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184264493
Principal investigator 1 Amgen Inc. $4,000.00 11/22/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246649880
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,850.00 11/21/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235998448
Principal investigator 1 Janssen Research & Development, LLC $12,330.00 11/07/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,041.22 11/07/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184258929
Principal investigator 1 Janssen Research & Development, LLC $9,447.00 11/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436467
Principal investigator 1 Janssen Research & Development, LLC $9,438.00 11/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436486
Principal investigator 1 Janssen Research & Development, LLC $3,337.00 11/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436540
Principal investigator 1 Janssen Research & Development, LLC $23,757.00 11/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436604
Principal investigator 1 Janssen Research & Development, LLC $1,257.00 11/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436663
Principal investigator 1 Janssen Research & Development, LLC $17,528.70 11/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175436627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $446.85 10/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,056.55 10/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,540.85 10/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $743.85 10/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,772.06 10/23/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184252576
Principal investigator 1 Celgene Corporation $28,000.00 10/22/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1222305584
Principal investigator 1 Janssen Research & Development, LLC $9,227.00 10/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436349
Principal investigator 1 Janssen Research & Development, LLC $5,404.00 10/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436405
Principal investigator 1 Janssen Research & Development, LLC $22,953.00 10/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436715
Principal investigator 1 Amgen Inc. $30,218.50 10/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246639859
Principal investigator 1 Janssen Research & Development, LLC $30,650.62 09/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436834
Principal investigator 1 Janssen Research & Development, LLC $44,500.00 09/26/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175436775
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,520.97 09/24/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235998444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,082.28 09/23/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184241614
Principal investigator 1 Janssen Research & Development, LLC $9,723.00 09/19/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,069.34 09/18/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184240448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,830.83 09/12/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184236540
Principal investigator 1 PFIZER INC. $1,519.00 09/02/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228753872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,015.06 08/26/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184230311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,689.78 08/21/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184229729
Principal investigator 1 Janssen Research & Development, LLC $410.33 08/18/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436343
Principal investigator 1 Janssen Research & Development, LLC $37,374.24 08/18/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436656
Principal investigator 1 Janssen Research & Development, LLC $9,834.00 08/18/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436780
Principal investigator 1 PFIZER INC. $10,269.00 08/18/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228766319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,704.84 08/14/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228301
Principal investigator 1 Janssen Research & Development, LLC $38,523.00 08/11/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,900.17 08/07/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184226123
Principal investigator 1 Janssen Research & Development, LLC $2,647.00 08/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,507.53 07/17/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49,160.41 07/10/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214342
Principal investigator 1 Janssen Research & Development, LLC $45,374.00 07/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436742
Principal investigator 1 Janssen Research & Development, LLC $9,399.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436413
Principal investigator 1 Janssen Research & Development, LLC $12,330.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436526
Principal investigator 1 Janssen Research & Development, LLC $12,330.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436768
Principal investigator 1 Janssen Research & Development, LLC $5,530.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436855
Principal investigator 1 Janssen Research & Development, LLC $7,564.00 06/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436430
Principal investigator 1 Janssen Research & Development, LLC $10,392.00 06/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436849
Principal investigator 1 PFIZER INC. $6,261.00 06/16/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228776839
Principal investigator 1 Janssen Research & Development, LLC $21,392.00 06/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436761
Principal investigator 1 Celgene Corporation $18,808.00 05/12/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305634
Principal investigator 1 PFIZER INC. $1,519.00 05/05/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228763271
Principal investigator 1 Janssen Research & Development, LLC $24,725.00 05/02/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436423
Principal investigator 1 Janssen Research & Development, LLC $26,509.00 04/11/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436435
Principal investigator 1 Amgen Inc. $23,163.79 03/27/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246639863
Principal investigator 1 PFIZER INC. $14,829.00 03/24/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228796817
Principal investigator 1 Celgene Corporation $46,057.00 03/19/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305582
Principal investigator 1 Janssen Research & Development, LLC $44,500.00 03/10/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175436508
Principal investigator 1 PFIZER INC. $25,496.92 03/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228781475
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $40,820.00 02/26/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235998446
Principal investigator 1 PFIZER INC. $1,519.00 02/24/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228797967
Principal investigator 1 Amgen Inc. $1,492.00 02/21/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246639861
Principal investigator 1 PFIZER INC. $8,348.00 02/10/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228793917
Principal investigator 1 Amgen Inc. $14.70 02/01/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246639865
Principal investigator 1 Amgen Inc. $23,496.00 01/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting No dispute reported 06/30/2026 1246639855
Principal investigator 1 AstraZeneca UK Limited $92,349.05 01/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185537615
Principal investigator 1 Amgen Inc. $129,783.63 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246639857
Principal investigator 1 AstraZeneca Pharmaceuticals LP $459,629.25 01/02/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185537613